Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to <12-Year-Olds.

IF 2.5 4区 医学 Q3 INFECTIOUS DISEASES
Lawrence D Sher, Justice K Boakye-Appiah, Sungeen Hill, Emily Wasserman, Xia Xu, Yvonne Maldonado, Emmanuel B Walter, Flor M Muñoz, Grant C Paulsen, Janet A Englund, Kawsar R Talaat, Elizabeth D Barnett, Satoshi Kamidani, Shelly Senders, Eric A F Simões, Kelly Belanger, Vrunda Parikh, Hua Ma, Xingbin Wang, Claire Lu, David Cooper, Kenneth Koury, Annaliesa S Anderson, Özlem Türeci, Uğur Şahin, Kena A Swanson, William C Gruber, Alejandra Gurtman, Nicholas Kitchin, Charu Sabharwal
{"title":"Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to <12-Year-Olds.","authors":"Lawrence D Sher, Justice K Boakye-Appiah, Sungeen Hill, Emily Wasserman, Xia Xu, Yvonne Maldonado, Emmanuel B Walter, Flor M Muñoz, Grant C Paulsen, Janet A Englund, Kawsar R Talaat, Elizabeth D Barnett, Satoshi Kamidani, Shelly Senders, Eric A F Simões, Kelly Belanger, Vrunda Parikh, Hua Ma, Xingbin Wang, Claire Lu, David Cooper, Kenneth Koury, Annaliesa S Anderson, Özlem Türeci, Uğur Şahin, Kena A Swanson, William C Gruber, Alejandra Gurtman, Nicholas Kitchin, Charu Sabharwal","doi":"10.1093/jpids/piae062","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>With the future epidemiology and evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uncertain, the use of safe and effective coronavirus disease 2019 (COVID-19) vaccines in pediatric populations remains important.</p><p><strong>Methods: </strong>We report data from two open-label substudies of an ongoing phase 1/2/3 master study (NCT05543616) investigating the safety and immunogenicity of a variant-adapted bivalent COVID-19 vaccine encoding ancestral and Omicron BA.4/BA.5 spike proteins (bivalent BNT162b2). The open-label groups presented here evaluate dose 4 with bivalent BNT162b2 in 6-month- to <12-year-olds who previously received three original (monovalent) BNT162b2 doses. In 6-month- to <5-year-olds, primary immunogenicity objectives were to demonstrate superiority (neutralizing titer) and noninferiority (seroresponse rate) to Omicron BA.4/BA.5 and noninferiority (neutralizing titer and seroresponse rate) to SARS-CoV-2 ancestral strains in participants who received bivalent BNT162b2 dose 4 compared with a matched group who received three doses of original BNT162b2 in the pivotal pediatric study (NCT04816643). In 5- to <12-year-olds, primary immunogenicity comparisons were descriptive. Reactogenicity and safety following vaccination were evaluated.</p><p><strong>Results: </strong>In 6-month- to <5-year-olds, dose 4 with bivalent BNT162b2 met predefined immunogenicity superiority and noninferiority criteria against Omicron BA.4/BA.5 and ancestral strains when compared with dose 3 of original BNT162b2. In 5- to <12-year-olds, bivalent BNT162b2 induced robust Omicron BA.4/BA.5 and ancestral strain neutralizing titers comparable with dose 3 of original BNT162b2. The safety profile for dose 4 of bivalent BNT162b2 given as dose 4 was consistent with that of original BNT162b2 in 6-month- to <12-year-olds. Reactogenicity events were generally mild to moderate. No adverse events led to discontinuation.</p><p><strong>Conclusions: </strong>These safety and immunogenicity data support a favorable benefit-risk profile for a variant-adapted BNT162b2 in children <12 years old.</p>","PeriodicalId":17374,"journal":{"name":"Journal of the Pediatric Infectious Diseases Society","volume":" ","pages":"421-429"},"PeriodicalIF":2.5000,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11344470/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Pediatric Infectious Diseases Society","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jpids/piae062","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: With the future epidemiology and evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uncertain, the use of safe and effective coronavirus disease 2019 (COVID-19) vaccines in pediatric populations remains important.

Methods: We report data from two open-label substudies of an ongoing phase 1/2/3 master study (NCT05543616) investigating the safety and immunogenicity of a variant-adapted bivalent COVID-19 vaccine encoding ancestral and Omicron BA.4/BA.5 spike proteins (bivalent BNT162b2). The open-label groups presented here evaluate dose 4 with bivalent BNT162b2 in 6-month- to <12-year-olds who previously received three original (monovalent) BNT162b2 doses. In 6-month- to <5-year-olds, primary immunogenicity objectives were to demonstrate superiority (neutralizing titer) and noninferiority (seroresponse rate) to Omicron BA.4/BA.5 and noninferiority (neutralizing titer and seroresponse rate) to SARS-CoV-2 ancestral strains in participants who received bivalent BNT162b2 dose 4 compared with a matched group who received three doses of original BNT162b2 in the pivotal pediatric study (NCT04816643). In 5- to <12-year-olds, primary immunogenicity comparisons were descriptive. Reactogenicity and safety following vaccination were evaluated.

Results: In 6-month- to <5-year-olds, dose 4 with bivalent BNT162b2 met predefined immunogenicity superiority and noninferiority criteria against Omicron BA.4/BA.5 and ancestral strains when compared with dose 3 of original BNT162b2. In 5- to <12-year-olds, bivalent BNT162b2 induced robust Omicron BA.4/BA.5 and ancestral strain neutralizing titers comparable with dose 3 of original BNT162b2. The safety profile for dose 4 of bivalent BNT162b2 given as dose 4 was consistent with that of original BNT162b2 in 6-month- to <12-year-olds. Reactogenicity events were generally mild to moderate. No adverse events led to discontinuation.

Conclusions: These safety and immunogenicity data support a favorable benefit-risk profile for a variant-adapted BNT162b2 in children <12 years old.

二价 Omicron BA.4/BA.5 BNT162b2 疫苗用于 6 个月至 12 岁以下儿童。
背景:由于SARS-CoV-2未来的流行病学和演变情况尚不确定,因此在儿科人群中使用安全有效的COVID-19疫苗仍然非常重要:我们报告了一项正在进行的1/2/3期主研究(NCT05543616)的两个开放标签子研究的数据,该研究调查了编码祖先和Omicron BA.4/BA.5尖峰蛋白的变异型二价COVID-19疫苗(二价BNT162b2)的安全性和免疫原性。本文介绍的开放标签组评估了剂量 4 与二价 BNT162b2 的 6 个月结果:6个月后得出结论:这些安全性和免疫原性数据支持变异型 BNT162b2 在儿童中具有良好的效益-风险特征。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of the Pediatric Infectious Diseases Society
Journal of the Pediatric Infectious Diseases Society Medicine-Pediatrics, Perinatology and Child Health
CiteScore
6.70
自引率
0.00%
发文量
179
期刊介绍: The Journal of the Pediatric Infectious Diseases Society (JPIDS), the official journal of the Pediatric Infectious Diseases Society, is dedicated to perinatal, childhood, and adolescent infectious diseases. The journal is a high-quality source of original research articles, clinical trial reports, guidelines, and topical reviews, with particular attention to the interests and needs of the global pediatric infectious diseases communities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信